Priovant's Lisraya receives first FDA approval as oral therapy for dermatomyositis

The U.S. Food and Drug Administration has cleared Priovant Therapeutics' daily TYK2/JAK1 inhibitor tablet, marketed under the name Lisraya, for the treatment of dermatomyositis in adults.

Lisraya is the inaugural orally administered targeted medication for this rare autoimmune condition, which has traditionally been managed with long‑term steroid therapy.

The approval grants a broad label that permits use in all adult patients, regardless of disease presentation or previous treatments, and the drug can be combined with existing therapies or serve as an alternative option.

Consistent with other drugs in the JAK inhibitor class, Lisraya carries a boxed warning highlighting risks of serious infections, malignancy, major cardiovascular events, thrombosis and death.

Analysts suggest the wide label and unmet need could position Lisraya for significant market uptake in the coming years.